Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesaglitazar add-on to sulphonylurea in poorly controlled type 2 diabetes
2004-001144-71Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tesaglitazar in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in HbA1c from baseline to week 24. Started Mar 2012; status: completed.
02
Drugs
tesaglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-001144-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001144-71.